MS Speaks

Multiple Sclerosis => MS - RESEARCH AND NEWS => Topic started by: agate on October 16, 2018, 02:57:48 pm

Title: (Abst.) Impact of trial design ... on identifying progressive MS therapies
Post by: agate on October 16, 2018, 02:57:48 pm
Although this abstract doesn't provide the specific information about clinical trials or treatments that are discussed in the article, it clearly states what many have long suspected: 



Quote
Since disability is multifaceted, progressive patients are heterogeneous, and the drivers of disease progression are still unclear, it has been difficult to identify the most informative outcome measures for progressive trials. Historically, secondary outcome measures have focused on inflammatory measures, which contributed to the recent identification of immunomodulatory therapies benefiting younger patients with more inflammatory progressive MS. Meanwhile, agents capable of treating late-stage disease have remained elusive.



From researchers at the University of Michigan, "Impact of trial design and patient heterogeneity  on the identification of clinically effective therapies for progressive MS," from Multiple Sclerosis Journal, October 10, 2018:


http://journals.sagepub.com/doi/abs/10.1177/1352458518800800